We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Early Ibuprofen Administration to Prevent Patent Ductus Arteriosus in Premature Newborn Infants

Anastasia Varvarigou, MD; Claudette L. Bardin, MD, PhD; Kay Beharry; Sylvain Chemtob, MD, PhD, FRCPC; Apostolos Papageorgiou, MD, FRCPC; Jacob V. Aranda, MD, PhD, FRCPC
JAMA. 1996;275(7):539-544. doi:10.1001/jama.1996.03530310045031.
Text Size: A A A
Published online


Objective.  —To test whether early postnatal (0 to 3 hours) intravenous administration of ibuprofen will prevent patent ductus arteriosus (PDA) in preterm neonates.

Design.  —Prospective sequential controlled trial with three treatment arms.

Setting.  —Level 3 perinatal-neonatal intensive care nursery.

Patients.  —Thirty-four premature newborn infants born from February to August 1993 with a mean birth weight of 913 g (range, 565 to 1460 g) and gestational age of 26.9 weeks (range, 22.4 to 31.0).

Intervention.  —Infants were consecutively assigned within 3 hours of age to treatment with either one dose of ibuprofen lysine (10 mg/kg intravenously) followed by 5 mg/kg per dose intravenously at 24 and 48 hours of age (n=12), one dose of ibuprofen Iysine (10 mg/kg intravenously; n=11), or saline (n=11).

Outcome Variables.  —Primary outcome variable was the presence of ductus arteriosus by echocardiography and clinical assessments at 3, 7, and 21 days of life. Secondary outcome variables included presence of intraventricular hemorrhage, renal function, ventilatory and oxygen needs, hematologic changes, gastrointestinal function, time to full enteral feeding, duration of hospitalization, and age at discharge.

Results.  —The three groups of patients were comparable in birth weight, gestational age, antenatal administration of betamethasone, and other perinatal characteristics. Ibuprofen treatment significantly reduced plasma levels of prostaglandins, and the levels remained low for 72 hours in newborns who received three doses of the drug. The incidence of PDA and other variables did not differ between patients who received a single dose of ibuprofen and those given saline. However, compared with the saline-treated newborns, babies who received three doses of ibuprofen had no PDA (0/12 vs 7/11 for saline; P<.02), had lower daily mean airway pressures (mean±SD, 5.2±1.1 cm H2O vs 8.3±2.8cm H2O for saline; P<.02) and better oxygenation index (2.6±0.6 vs 4.7±1.8 for saline; P<.02) at the end of the first week of life, and required fewer days of ventilation (25±14 days vs 44±26 days for saline; P<.03). Babies given three doses of ibuprofen tended to tolerate full oral feedings earlier (35±19 days vs 56±34 days for saline; P=.09), had shorter duration of hospitalization (71.2±22.6 days vs 127.3±74.7 days for saline; P<.05), and were discharged to home at an earlier postconceptional age (37.8±2.0 weeks vs 44.8±9.8 weeks for saline; P<.05). Ibuprofen treatment in this phase I trial was not associated with any apparent early neurological, intestinal, renal, hepatic, or hematologic complications.

Conclusions.  —Administration of three doses of ibuprofen within 3 hours after birth in preterm neonates reduced the incidence of PDA without causing notable early adverse drug reactions in this phase I trial. Early closure of the ductus arteriosus was also associated with better respiratory outcome and earlier discharge from the hospital.(JAMA. 1996;275:539-544)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.